Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Price Up 24.5% – Time to Buy?

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX)’s share price was up 24.5% during trading on Monday . The stock traded as high as $15.45 and last traded at $15.05. Approximately 392,691 shares changed hands during mid-day trading, a decline of 62% from the average daily volume of 1,044,757 shares. The stock had previously closed at $12.09.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wall Street Zen raised Quoin Pharmaceuticals to a “sell” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Quoin Pharmaceuticals in a research note on Monday, December 1st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Quoin Pharmaceuticals Price Performance

The firm has a market capitalization of $12.64 million, a price-to-earnings ratio of -0.47 and a beta of 1.58. The stock has a 50 day moving average price of $13.80 and a two-hundred day moving average price of $10.13.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its earnings results on Thursday, November 6th. The company reported ($6.71) EPS for the quarter, missing analysts’ consensus estimates of ($6.36) by ($0.35). As a group, research analysts expect that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -2.05 earnings per share for the current fiscal year.

Insider Activity at Quoin Pharmaceuticals

In other Quoin Pharmaceuticals news, Director Dennis Langer acquired 15,152 shares of the stock in a transaction dated Tuesday, October 14th. The stock was acquired at an average price of $8.49 per share, with a total value of $128,640.48. Following the completion of the purchase, the director owned 15,153 shares in the company, valued at $128,648.97. This trade represents a 1,515,200.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 13.46% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.